Atlas Trials

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

Clinical trial NCT03564158 · COMPLETED

Trial details

NCT number
NCT03564158
Sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2018-05-01
Primary completion
2018-11-19
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.